Clinical and Radiologic Features of a Cohort of Adult and Pediatric Patients in the Pacific Northwest with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) (P13-5.022)

Abstract

<h3>Objective:</h3> To describe a cohort of patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) seen at a tertiary center in the pacific northwest. <h3>Background:</h3> MOGAD is a newly described clinical entity comprised of various presentations of optic neuritis, transverse myelitis, acute disseminated encephalomyelitis (ADEM), encephalitis, and seronegative NMOSD. Patients may sustain only one attack or have a relapsing course necessitating immunotherapy for relapse prevention. Prior reports note that MOGAD is more commonly monophasic in children (up to 70%), though 30–80% of children and adults with MOGAD will go on to have relapses and there is no way to predict who is at risk. <h3>Design/Methods:</h3> This was a single-center retrospective cohort study. <h3>Results:</h3> This preliminary sample consisted of 56 patients (20 pediatric, 36 adult) with a diagnosis of MOGAD evaluated at least once at our center between January 2017 and October 2022. Non-Hispanic White (55.4%) and Hispanic (30.4%) comprised the majority of the sample. The median age during index event was 9.27 years in the pediatric subset and 36.1 in the adults. Amongst the whole cohort, the most common presentation at onset was optic neuritis (58.9%) though the majority of pediatric cases presented with (ADEM) (40.0%). The pediatric group had more patients with relapsing disease (70.0%) compared to the adult group (55.6%). Half of relapsing pediatric patients had their first relapse more than a year after the index event with a median time to first relapse of 15.5 months. The median time to first relapse in the adult group was 7.0 months. None of the patients in the pediatric group were started on immunotherapy for relapse prevention prior to the first relapse though a subset of adult patients were (19.4%). <h3>Conclusions:</h3> This study is the first to describe the demographic and clinical features of a unique sample of patients with MOGAD evaluated in the pacific northwest. <b>Disclosure:</b> Dr. Martin has received research support from Tartar Trust. The institution of Dr. Martin has received research support from OHSU Foundation. Mrs. Srikanth has nothing to disclose. Dr. Angappan has nothing to disclose. Miss Srikanth has nothing to disclose. Dr. Kanwar has nothing to disclose. Miss Mazmanyan has nothing to disclose. Julie Falardeau has nothing to disclose. David Pettersson has nothing to disclose. Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceuticals. Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb Foundation. Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD-Serono . The institution of Dr. Yadav has received research support from Department of Veterans Affairs. Dr. Yadav has received research support from NIH. Dr. Yadav has received research support from PCORI. Dr. Yadav has received research support from NMSS. The institution of Dr. Yadav has received research support from Department of Veterans Affairs. The institution of Dr. Yadav has received research support from Tykeson Family Foundation Endowed Professorship.